Biotech Values

[loparn]

"AdaptVac reaches proof of concept in animals for breakthrough breast cancer vaccine treatment"

https://www.pressesystemet.dk/pressemeddelelser/adaptvac-reaches-proof-of-concept-in-animals-for-breakthrough-breast-cancer-vaccine-treatment-14055/

"AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, combining ExpreS2ion's platform with novel proprietary and groundbreaking Virus-Like Particle (VLP) technology, developed at the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders."

ExpreS2ion Biotech Holding is listed on Nasdaq Stockholm First North.

https://finance.yahoo.com/quote/EXPRS2.ST?p=EXPRS2.ST

ExpreS2ion's home page http://expres2ionbio.com/

There will be a presentation of the breast cancer project against HER2 November 30 in Singapore titled :

"A novel VLP-display technology enables induction of protective antibody
responses directed against human HER2 in a transgenic mouse model of
spontaneous breast cancer"

http://www.meetingsmanagement.co.uk/images/stories/pdf/vlpnpv-2017-leaflet.pdf